A new bill has been proposed in the United States that is purportedly aimed at reducing drug prices.  The proposed legislation would create a Bureau of Prescription Drug Affordability and Access and is purportedly modelled after Canada’s Patented Medicine Prices Review Board.  In Canada, the Patented Medicine Prices Review Board is responsible for reviewing the prices of patented medicines sold in Canada, among other responsibilities.  The board considers many factors, including comparison to the drug prices in some other countries.

However, the bill proposed in the United States would allow the bureau to void patents providing exclusive manufacture and use of the drug in an effort to allow others to produce a generic version of the drug at a reduced cost.

More information can be found here.